Study protocol:
Data Extraction:
All articles that were of good quality under the Strobe checklist entered the data collection stage. To extract the data from the articles, a checklist was already prepared by researchers to extract the necessary information such as the name of the author, the year of the study, the place where the study took place, the men who had consumed metformin and were afflicted to prostate cancer, the men who had not taken metformin but had prostate cancer, the men who had taken metformin and had no prostate cancer and the men who had not taken metformin and have no prostate cancer.
Statistical Analysis:
To evaluate the effect of metformin on the risk of prostate cancer in men compared to the control group, the odds ratio (OR) index was used. In order to combine the results of the studies, OR logarithms were used in each study and the I 2 index and Cochran Q test were used to check the heterogeneity of the studies. (Fig. 3) . The analysis of publication bias showed that there was no probable publication bias in the studies because P = 0.524.That is, most of the published studies in this area were covered as a result of the search for studies, and the article search phase has been completely done.
Discussion:
In the 11 studies we explored, it was concluded that taking metformin would reduce by 0.89 the risk of prostate cancer in men. As we see in Table 1 , in four studies, the odds ratio of metformin use to reduce the risk of prostate cancer is not significant, and in the other 7 studies it is significant, and overall the effect of metformin on reducing the risk of prostate cancer is not statistically significant (Table 1) 
Conclusion:
The odds ratio of metformin use for reducing prostate cancer was 0.89 (95% confidence intervalCI: 0.67-1.17), which was not statistically significant. Given the variability in the results of various studies and the limited number of studies, more clinical studies are needed to provide a definitive opinion on the metformin intake effect or lack thereof on the decline of prostate cancer. Metformin consumption was a preventive factor in prostate cancer in the continents of Asia, Europe and the United States, although all three were not statistically significant. In studying the results derived from several distinct countries, we also found that metformin was a preventive factor in prostate cancer in Taiwan, Switzerland and Denmark, which was statistically significant, but the results of other countries were not statistically significant. In the analysis which was conducted based on different treatment durations of the patients, the odds ratio (OR) for the group treated under 5 years was less than the group treated for 5 to 10 years. In both groups, metformin had a preventive role in prostate cancer, but both were not statistically significant.
Regarding the age of the patients it can be noted that as the age of the patients increases, the odds ratio (OR) also increases. In other words, in the 64-70 age group, metformin has a preventive role in prostate cancer and is not statistically significant. But in the 71 to 77 age group, metformin is a risk factor for prostate cancer, which is still not statistically significant.
